Menopausal Disorders - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 39 pages report, published by Global Markets Direct

Keywords : Menopausal Disorders Therapeutic Products under Development, Key Players in Menopausal Disorders Therapeutics, Menopausal Disorders Pipeline Overview, Menopausal Disorders Pipeline, Menopausal Disorders Pipeline Assessment

Report ThumbnailSeptember-2013
Menopausal Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Menopausal Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Menopausal Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Disorders. Menopausal Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Menopausal Disorders.
- A review of the Menopausal Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Menopausal Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Menopausal Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Menopausal Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Menopausal Disorders, H2 2013 7
  • Products under Development for Menopausal Disorders - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Early Clinical Stage Products, H2 2013 13
  • Pre-Clinical Stage Products, H2 2013 14
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Combination Products, H2 2013 21
  • Assessment by Route of Administration, H2 2013 22
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Molecule Type, H2 2013 24
  • Assessment by Stage and Molecule Type, H2 2013 25
  • List of Tables
  • Number of Products Under Development for Menopausal Disorders, H2 2013 7
  • Products under Development for Menopausal Disorders - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
  • Products under Development by Companies, H2 2013 15
  • Products under Investigation by Universities/Institutes, H2 2013 16
  • Paladin Labs Inc., H2 2013 17
  • Pantarhei Bioscience BV, H2 2013 18
  • EndoCeutics, Inc., H2 2013 19
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Combination Products, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 25
  • Menopausal Disorders Therapeutics - Drug Profile Updates 31
  • Menopausal Disorders Therapeutics - Dormant Products 32
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Menopausal Disorders Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Menopausal Disorders 7
  • Menopausal Disorders Therapeutics under Development by Companies 9
  • Menopausal Disorders Therapeutics under Investigation by Universities/Institutes 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Early Clinical Stage Products 13
  • Comparative Analysis 13
  • Pre-Clinical Stage Products 14
  • Comparative Analysis 14
  • Menopausal Disorders Therapeutics - Products under Development by Companies 15
  • Menopausal Disorders Therapeutics - Products under Investigation by Universities/Institutes 16
  • Companies Involved in Menopausal Disorders Therapeutics Development 17
  • Paladin Labs Inc. 17
  • Pantarhei Bioscience BV 18
  • EndoCeutics, Inc. 19
  • Menopausal Disorders - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Combination Products 21
  • Assessment by Route of Administration 22
  • Assessment by Molecule Type 24
  • Drug Profiles 26
  • (estradiol + testosterone) - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • BLACE - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • (prasterone + acolbifene) - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • (estradiol + progesterone) - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • Troglitazone Compounds For Climacteric And Cancer - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • Menopausal Disorders Therapeutics - Drug Profile Updates 31
  • Menopausal Disorders Therapeutics - Dormant Products 32
  • Menopausal Disorders - Product Development Milestones 33
  • Featured News & Press Releases 33
  • Aug 07, 2012: TherapeuticsMD Announces FDA Accepts IND Application For TX12002HR 33
  • Jun 25, 2010: Merck Challenges Verdict in Federal FOSAMAX (alendronate sodium) Trial 33
  • Jun 07, 2010: Statement on FOSAMAX (alendronate sodium) Product Liability Trial in U.S. District Court 33
  • May 05, 2010: Merck Wins Second Federal FOSAMAX (alendronate sodium) Bellwether Trial 34
  • Dec 14, 2009: Ablynx Initiates Phase I Trial Study Of ALX-0141 For The Treatment Of Postmenopausal Women 34
  • Nov 23, 2009: Merck Wins Summary Judgment in Second Federal Bellwether Case Involving FOSAMAX (alendronate sodium) 35
  • Sep 11, 2009: Mistrial Declared in First Federal FOSAMAX Trial 35
  • Sep 03, 2009: Bionovo To Present Positive Results From Phase 2 Trial Of Menerba For Vasomotor Symptoms To The International Community 36
  • Jul 29, 2009: Statement by Merck & Co., Inc., Regarding FOSAMAX (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw 37
  • Mar 12, 2008: Wyeth withdrew EU medicines agency application to approve Pristiq 37
  • Appendix 38
  • Methodology 38
  • Coverage 38
  • Secondary Research 38
  • Primary Research 38
  • Expert Panel Validation 38
  • Contact Us 39
  • Disclaimer 39

Please select a license type

Share

Related Products

Global Markets DirectMenopausal Disorders - Pipeline Review, H2 2013Product ThumbnailMenopausal Disorders - Pipeline Review, H2 2013, Industry ReportProduct #: 113328
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved